Great Trades

Thursday, February 02, 2006

Morgan Joseph Initiates INCY with a Buy and $8 Target

From Briefing.com:

"Morgan Joseph initiates INCY with a Buy and $8 tgt. They note that the co's lead product candidate, DFC, is currently in Phase IIb development as a once-daily oral therapy for HIV. They anticipate positive results from this study, which should become available in 1H07. They also believe the co's CCR2 program, recently partnered with Pfizer (PFE), could translate into substantial revenues in the form of milestones and royalties.

They believe newsflow from other internal programs, including novel sheddase inhibitors for cancer (currently in Phase I/II dose-ranging studies) and an oral CCR5 antagonist for HIV (Phase I slated to begin in 1H06), will boost investor interest."


INCY reports earnings before the market open on Thursday, February 16. You can access the conference call that morning here: http://biz.yahoo.com/cc/6/64726.html.

posted by GreatTrades  # 12:48 PM

Archives

December 2005   January 2006   February 2006   March 2006   April 2006   May 2006   July 2006   August 2006   October 2006   November 2006   December 2006   January 2007   February 2007   March 2007   April 2007   May 2007   June 2007   August 2007   October 2007   November 2007   May 2008   September 2008   October 2008   January 2009   February 2009   March 2009   April 2009   May 2009   June 2009   July 2009   August 2009   September 2009   October 2009   November 2009   December 2009   March 2010   May 2010   June 2010  

Great Trades Home    Email GreatTrades

Disclaimer: Great Trades may have a position in all or some of the stocks discussed in this blog, but is not paid by any company to promote their stock. Great Trades contains opinions, none of which constitute a recommendation that any particular security, transaction, or investment strategy is suitable for any specific person. Great Trades does not provide personalized investment advice.